KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Jazz Pharmaceuticals (JAZZ) Invested Capital (2016 - 2025)

Historic Invested Capital for Jazz Pharmaceuticals (JAZZ) over the last 17 years, with Q3 2025 value amounting to $9.3 billion.

  • Jazz Pharmaceuticals' Invested Capital fell 936.2% to $9.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $9.3 billion, marking a year-over-year decrease of 936.2%. This contributed to the annual value of $10.2 billion for FY2024, which is 796.26% up from last year.
  • As of Q3 2025, Jazz Pharmaceuticals' Invested Capital stood at $9.3 billion, which was down 936.2% from $9.1 billion recorded in Q2 2025.
  • In the past 5 years, Jazz Pharmaceuticals' Invested Capital registered a high of $10.9 billion during Q2 2021, and its lowest value of $5.9 billion during Q1 2021.
  • Moreover, its 5-year median value for Invested Capital was $9.4 billion (2024), whereas its average is $9.3 billion.
  • As far as peak fluctuations go, Jazz Pharmaceuticals' Invested Capital skyrocketed by 10723.89% in 2021, and later tumbled by 1707.74% in 2022.
  • Jazz Pharmaceuticals' Invested Capital (Quarter) stood at $10.0 billion in 2021, then dropped by 12.03% to $8.8 billion in 2022, then rose by 7.26% to $9.4 billion in 2023, then rose by 7.96% to $10.2 billion in 2024, then dropped by 8.65% to $9.3 billion in 2025.
  • Its Invested Capital stands at $9.3 billion for Q3 2025, versus $9.1 billion for Q2 2025 and $9.5 billion for Q1 2025.